Department of Thoracic Surgery, North Hospital - APHM, Aix-Marseille University, Marseille, France.
Department of Public Health, North Hospital, EA 3279 Research Unit, Aix-Marseille University, Marseille, France.
J Thorac Cardiovasc Surg. 2015 Jan;149(1):73-82. doi: 10.1016/j.jtcvs.2014.09.063. Epub 2014 Sep 28.
The study objective was to determine contemporary early outcomes associated with pneumonectomy for lung cancer and to identify their predictors using a nationally representative general thoracic surgery database (EPITHOR).
After discarding inconsistent files, a group of 4498 patients who underwent elective pneumonectomy for primary lung cancer between 2003 and 2013 was selected. Logistic regression analysis was performed on variables for mortality and major adverse events. Then, a propensity score analysis was adjusted for imbalances in baseline characteristics between patients with or without neoadjuvant treatment.
Operative mortality was 7.8%. Surgical, cardiovascular, pulmonary, and infectious complications rates were 14.9%, 14.1%, 11.5%, and 2.7%, respectively. None of these complications were predicted by the performance of a neoadjuvant therapy. Operative mortality analysis, adjusted for the propensity scores, identified age greater than 65 years (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.5-2.9; P < .001), underweight body mass index category (OR, 2.2; 95% CI, 1.2-4.0; P = .009), American Society of Anesthesiologists score of 3 or greater (OR, 2.310; 95% CI, 1.615-3.304; P < .001), right laterality of the procedure (OR, 1.8; 95% CI, 1.1-2.4; P = .011), performance of an extended pneumonectomy (OR, 1.5; 95% CI, 1.1-2.1; P = .018), and absence of systematic lymphadenectomy (OR, 2.9; 95% CI, 1.1-7.8; P = .027) as risk predictors. Induction therapy (OR, 0.63; 95% CI, 0.5-0.9; P = .005) and overweight body mass index category (OR, 0.60; 95% CI, 0.4-0.9; P = .033) were protective factors.
Several risk factors for major adverse early outcomes after pneumonectomy for cancer were identified. Overweight patients and those who received induction therapy had paradoxically lower adjusted risks of mortality.
本研究旨在确定肺癌肺切除术的当代早期结果,并使用全国代表性的胸外科数据库(EPITHOR)确定其预测因素。
在剔除不一致的文件后,选择了 2003 年至 2013 年间进行择期肺癌肺切除术的 4498 例患者。对死亡率和主要不良事件的变量进行 logistic 回归分析。然后,对接受或不接受新辅助治疗的患者的基线特征进行倾向评分分析。
手术死亡率为 7.8%。手术、心血管、肺部和感染并发症的发生率分别为 14.9%、14.1%、11.5%和 2.7%。这些并发症都没有被新辅助治疗所预测到。调整倾向评分后,手术死亡率分析发现年龄大于 65 岁(比值比[OR],2.1;95%置信区间[CI],1.5-2.9;P<0.001)、体重不足的 BMI 类别(OR,2.2;95%CI,1.2-4.0;P=0.009)、美国麻醉师协会评分 3 或更高(OR,2.310;95%CI,1.615-3.304;P<0.001)、手术右侧(OR,1.8;95%CI,1.1-2.4;P=0.011)、进行扩展肺切除术(OR,1.5;95%CI,1.1-2.1;P=0.018)和未行系统性淋巴结切除术(OR,2.9;95%CI,1.1-7.8;P=0.027)为风险预测因素。诱导治疗(OR,0.63;95%CI,0.5-0.9;P=0.005)和超重 BMI 类别(OR,0.60;95%CI,0.4-0.9;P=0.033)是保护因素。
确定了肺癌肺切除术后发生主要不良早期结果的几个危险因素。超重患者和接受诱导治疗的患者的死亡率调整风险反而降低。